Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

Eli Lilly HQ

Lilly acquires rights to intranasal glucagon spray

Could be first needle-less emergency treatment for hypoglycaemia

- PMLiVE

AZ halts durvalumab combination trials on safety grounds

Saysmove is a precautionary step after respiratory disease reports

Bristol-Myers Squibb (BMS) building

BMS gets OK for broader Opdivo use in lung cancer

US regulator'sdecision allows firm to edge in front of Merck & Co's Keytruda

- PMLiVE

Ovid Therapeutics adds member to scientific advisory board

Dr Jerome Zeldis joins the firm

Infographic: Spondyloarthritis

Overview of spondyloarthritis patient profiles and treatment pathways.

Inizio

Webinar: Demand assessment – Reflecting real world choices

How study design which reflects doctors’ real world choices can optimise results.

Inizio

Evaluating the potential of a pre-launch prodct in a real-life setting

Using in-depth-interviews as well as a SmartPhone app to collect real patient cases from physicians to find out opportunity for a new product.

Inizio

Blue Latitude Health shortlisted for two PMEA 2015 awards

Blue Latitude Health’s Medical Information Cascade project for Eli Lilly and Company has been shortlisted in the Excellence in Physicians/Healthcare Provider Support Programmes and Innovation categories.

Blue Latitude Health

Boehringer Ingelheim headquarters

Boehringer says anti-IL-23 drug beats Stelara in psoriasis trial

Interleukin-23 inhibitor outperforms Johnson & Johnson's blockbuster

National Institute for Health and Care Excellence NICE logo

NICE recommends Keytruda for advanced skin cancer

Second recommendation for drug in a week

- PMLiVE

Neurocrine plans movement disorder drug filing in 2016

NBI-98854 in trials for tardive dyskinesia

Ritter Pharmaceuticals appoints new CMO

AnnKatrin Petersen-Jappelli to strengthen company

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links